Targeted Therapies in Oncology, an oncology publication that provides oncology professionals with cutting-edge research, data, and treatment strategies surrounding molecular and immune system targets, has appointed Robert L. Ferris, M.D., Ph.D., as its co-physician editor-in-chief.
We look forward to having Dr. Ferris joining the Targeted Therapies in Oncology team, said Michael J. Hennessy Jr., president of MJH Associates Inc., parent company of Targeted Oncology. „¢ His impeccable experience and contributions in the field of immunology and oncology will help improve our teams ability to deliver unprecedented information and data to our audience.
In this role, Dr. Ferris will work closely with the editorial team to promote major targeted therapy innovations and updates. He will also be joining Arjun V. Balar, M.D., as co-physician editor-in-chief of the publication. The addition of Dr. Ferris will allow Targeted Therapies in Oncology to double its frequency and begin publishing two issues every month. This new publishing schedule will begin in December 2018.
I am delighted to assist Targeted Therapies in Oncology in its mission to disseminate important and exciting advances in the rapidly emerging new treatments in cancer research and treatment, said Ferris. Targeted Therapies in Oncology is truly a gem, and I look forward to helping it continue as a valuable resource for oncologists.
Dr. Ferris is the director of the University of Pittsburgh Medical Centers Hillman Cancer Center, the Hillman professor of oncology, associate vice chancellor for cancer research and co-director of the Tumor Microenvironment Center. His research primarily focuses on cellular immune mechanisms of natural killer cells, dendritic cells, and T-lymphocyte activation against head and neck cancer tumor antigens. His group also conducts research on mechanisms of tumor antigen processing and immunologic evasion used by head and neck cancer cells.
For more information on Targeted Therapies in Oncology, visit www.targetedonc.com.
About Targeted Oncology„¢
TargetedOnc.com provides the latest news and insight on next-generation therapeutics and their molecular targets for practicing community-based oncologists. As the field of oncology continues to trend toward systemic biology and molecular aberrations, the challenges facing many oncologists is staying up-to-date with the future of cancer therapeutics. As such, TargetedOnc strives to provide the latest information on breaking news and updates on the burgeoning field. TargetedOnc focuses on the next stage of cancer development, on cutting edge therapies and their biological targets. Content is organized by tumor type, news and conference coverage.